What’s Propelling ZIOPHARM Oncology Inc. (ZIOP) to Increase So Much?

August 28, 2017 - By Adrian Erickson

The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is a huge mover today! The stock increased 7.36% or $0.42 during the last trading session, reaching $6.13. About 2.28M shares traded or 152.60% up from the average. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has risen 1.75% since August 28, 2016 and is uptrending. It has underperformed by 14.95% the S&P500.
The move comes after 7 months positive chart setup for the $870.23 million company. It was reported on Aug, 28 by Barchart.com. We have $6.38 PT which if reached, will make NASDAQ:ZIOP worth $34.81 million more.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Ratings Coverage

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology had 6 analyst reports since December 4, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Mizuho on Monday, January 25. The firm has “Neutral” rating by Mizuho given on Wednesday, May 11. The rating was upgraded by Wells Fargo to “Market Perform” on Wednesday, August 10. On Thursday, June 2 the stock rating was initiated by Raymond James with “Market Perform”. The company was initiated on Friday, December 4 by Wells Fargo.

More recent ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) news were published by: Zacks.com which released: “Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock August 28 …” on August 28, 2017. Also Seekingalpha.com published the news titled: “Sky’s The Limit For Ziopharm” on August 03, 2017. Seekingalpha.com‘s news article titled: “ZIOPHARM Oncology’s (ZIOP) CEO Laurence Cooper on Q2 2017 Results – Earnings …” with publication date: August 01, 2017 was also an interesting one.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The company has market cap of $870.23 million. The Firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral therapies for the treatment of cancer and graft-versus-host-disease. It currently has negative earnings. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System expression platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.